SPRO— AI Stock Forecast & Price Targets
Published 7/29/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live SPRO price forecast →
SPRO is a $68M micro-cap binary optionality story where two transformative deals ($105M non-dilutive KKR royalty and Innovent's SP001/CD40L license worth up to $1.1B) have been systematically distributed into, driving price to a fresh 52-week low of $1.20 with RSI ~22 and price ~50% below the 200-SMA. Q1'26 revenue collapsed 95% Q/Q to $258K, confirming no recurring operating business, and the Aug 11 earnings print is a binary event with no cushion. Balance sheet is clean ($56.1M cash, current ratio 10.5) but the tape is telling us informed sellers do not believe the milestone waterfall until it's proven.
HOLD/AVOID new entries into the Aug 11 earnings print. This is a binary event with no cushion (Q1 revenue $258K), and IV crush plus a potential guide-down on cash burn creates an unattractive risk/reward. If already long, tighten stops just below $1.08 (52w-low); a break there opens a vacuum to $0.80-$0.95. Do not chase any bounce into the print. A tactical trade only sets up on a reclaim of $1.27 with volume ahead of earnings, targeting $1.40 — otherwise sit out. Do not size the model's bullish 1h forecast to $2.30+; its realized accuracy is below the naive baseline in this regime.
1-6 month view is HOLD with negative skew. Post-earnings, the key question is whether the Innovent upfront outflow cadence forces a cash-preservation narrative or leaves the KKR facility fully accretive. Base case: price grinds in a $1.10-$1.60 range with occasional squeezes on SP001 dosing/enrollment updates, no fundamental re-rating until a Phase 2 readout materializes in ~2027. Bull case requires (i) $1.27 reclaim, (ii) institutional ownership rising from 14.5%, and (iii) a clean earnings print with Utebzi royalty color. Bear case is a break of $1.08 into distressed-financing territory. Change my mind: institutional accumulation disclosure, insider buying above 26% ownership, or a clean CD40L safety readout from a competitor.
1-3 year terminal thesis is a bimodal outcome. Bull path: SP001 delivers Phase 2 IgG4-RD data in Q2'27, triggering significant Innovent milestones and re-rating the equity toward $3-5 on a de-risked immunology platform plus scaling Utebzi royalties. Bear path: CD40L class safety signal, Phase 2 failure, or milestone timing forces distressed dilution — equity toward $0.50 or worse. Structural risks: (i) no recurring operating business, (ii) CD40L class thrombosis history, (iii) dependence on GSK's Utebzi commercial execution, (iv) micro-cap liquidity where informed sellers exit into every catalyst. This is a call option on SP001, not a business — size accordingly.
The Q1'26 print laid bare the structural reality: revenue of just $258K (down 95% Q/Q from the $39.7M milestone-inflated Q4'25) with an operating loss of $7.5M confirms there is no recurring business, only lumpy milestone accounting. Headline TTM ratios (P/E 4.9, ROE 35%, profit margin 27.8%) are artifacts of the one-off Utebzi/GSK milestone and should be ignored. The balance sheet is genuinely a bright spot — $56.1M cash vs $2.5M debt, current ratio 10.5, book/sh $0.91 (roughly 75% of price is net cash), and free cash flow +$15.9M in Q1 from milestone timing. The $105M non-dilutive HCRx/KKR facility further monetizes future Utebzi royalties without shareholder dilution, extending runway well into 2028. However, the Innovent 8-K flags large upfront and milestone outflows that will burn through this cushion, and forward EPS of -$1.11 confirms a return to loss-making. Capital allocation is defensible (non-dilutive financing, pivoting to immunology via SP001) but the market is pricing execution risk, not the book value.
The chart is unambiguously broken across every timeframe. On the 1h chart, price collapsed from a $2.10 shelf around July 10 straight to $1.20 in a single vertical move (a ~43% gap-and-crush on the Innovent/KKR headlines) and has since gone dead flat — classic capitulation with no reflex bounce. The 4h and 1d confirm a broken multi-quarter range: $3.00 (June high) → $2.20 (prior support) → $1.40 → $1.27 → now $1.20, sitting only $0.12 above the $1.08 52w-low. RSI 21.8 is oversold but the lessons here are explicit: oversold does not equal buyable in this name. Price is -31.6% below SMA20, -47.2% below SMA50, -49.8% below SMA200 — this is a full downtrend, not a pullback. Short float has risen from 4.3% to ~4.9% but ratio is only 1.35 days, so a squeeze is unlikely to be violent. The forecast band is bullish (1h and 4h models expect a rebound to ~$2.30-$3.00), but the model's own realized directional accuracy is 33-49% versus 83-93% for the naive baseline — the model is being systematically fooled by mean-reversion in a trending name, and its forecast should be heavily discounted. Key levels: $1.08 (52w-low, must hold), $1.27 (first reclaim needed), $1.40 (regime shift signal); downside vacuum below $1.08 opens $0.80-$0.95.
The signal is the July 14 8-K trifecta: (1) Innovent in-licensing of IBI355 (anti-CD40L for IgG4-RD and other immunology indications) with up to $1.1B in downstream milestones, (2) a $105M non-recourse, non-dilutive royalty financing with HealthCare Royalty (majority owned by KKR) collateralized against future Utebzi royalties from GSK, and (3) confirmation of large upfront/milestone outflows to Innovent. On paper this is transformative — a pivot to immunology with fully-funded Phase 2 optionality and no equity dilution. In practice, the tape sold every headline: SPRO went from $1.57 pre-announcement to a $1.08 low, closing at $1.20. That is informed distribution, not disbelief in the science — likely reflecting concern about (a) CD40L class thrombosis history, (b) upfront cash outflows to Innovent hitting before Utebzi royalties scale, and (c) the ~2027 timeline to Phase 2 data. Broader biotech news (J&J oncology miss, AstraZeneca lung cancer deal) is noise. Retail sentiment is 100% bullish, which in this name has been a reliable contrarian tell.
- SP001/IBI355 Phase 2 initiation in IgG4-RD targeted Q2'27, gating up to $1.1B in Innovent milestones
- $105M HCRx/KKR non-dilutive facility fully funds SP001 Phase 2 without equity issuance, extending runway to 2028
- Utebzi (tebipenem HBr) US commercial ramp under GSK post-June 2026 FDA approval — anchor royalty stream backing the KKR facility
- SPR206 regional milestones from Everest Medicines (Greater China, SK, SEA) — optional non-dilutive income
- CD40L platform expansion beyond IgG4-RD into broader autoimmune indications if Phase 2 de-risks safety
- Aug 11 earnings is binary — Q1'26 revenue $258K provides no cushion for a cash burn or guide-down surprise
- CD40L class-wide thromboembolism history: any competitor safety signal could collapse the entire SP001 milestone waterfall
- Innovent upfront/milestone cash outflows may hit before Utebzi royalties scale, forcing a distressed equity raise
- Every positive catalyst ($1.1B Innovent, $105M KKR) has been systematically distributed into — informed selling pressure is the dominant signal
- Price sits $0.12 above 52w-low $1.08; a break opens a technical vacuum toward $0.80-$0.95
- Short float rising 4.3% → 4.9% signals fresh bearish positioning ahead of the print
- Institutional ownership only 14.5% and trending -1.5% — no smart-money accumulation to backstop
- Model forecasts (bullish 1d/1wk) have been beaten by naive baseline and should be discounted heavily
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord